Drug Profile
Research programme: protein tyrosine phosphatase-1B inhibitors - Alinea Pharmaceuticals/The Institute for Diabetes Discovery
Alternative Names: IDD-3-IDD; IDD-3-Institute for Diabetes Discovery; Protein tyrosine phosphatase-1B inhibitors research programme - Alinea Pharmaceuticals/The Institute for Diabetes DiscoveryLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Institute for Diabetes Discovery LLC
- Class Small molecules
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 31 Aug 2005 The Institute for Diabetes Discovery and Alinea Pharmaceuticals have entered into an agreement to co-develop protein tyrosine phosphatase inhibitors for Type-2 diabetes
- 17 Jun 2004 Preclinical trials in Type-2 diabetes mellitus in USA (PO)